Inhibitors of the PLK1 polo-box domain: drug design strategies and therapeutic opportunities in cancer.

The PBD has emerged as a viable alternative target for the inhibition of PLK1, and progress has been made in using compounds to elucidate mechanistic aspects of activity regulation and in determining roles of the PBD. Studies have resulted in proof of concept of efficacy suggesting promise for PBD binders in clinical development.